NCT03141463View on ClinicalTrials.gov

Vvax001 Cancer Vaccine in (Pre) Malignant Cervical Lesions

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 13, 2017

Primary Completion Date

November 28, 2017

Study Completion Date

November 28, 2017

Conditions
CIN 2/3Cervical Cancer
Interventions
BIOLOGICAL

Vvax001 therapeutic cancer vaccine

Vvax001 is a vaccine consisting of a replication-incompetent Semliki Forest Virus (SFV) vector encoding HPV-derived tumor antigens. Patients will receive three consecutive doses, with an interval of 3 weeks.

Trial Locations (1)

9700 RB

University Medical Center Groningen, Groningen

All Listed Sponsors
collaborator

Dutch Cancer Society

OTHER

collaborator

ViciniVax B.V

UNKNOWN

lead

University Medical Center Groningen

OTHER

NCT03141463 - Vvax001 Cancer Vaccine in (Pre) Malignant Cervical Lesions | Biotech Hunter | Biotech Hunter